drugset / Trial / NCT04303247
CD19 and CD22 Dual-targeted CAR-T Cells for Relapsed or Refractory B-NHL
Phase 0
Unknown
30 enrolled
Xinqiao Hospital of Chongqing
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China · collabChongqing University Cancer Hospital · collabGracell Biotechnologies (Shanghai) Co., Ltd. · collabTang-Du Hospital · collabThe Affiliated Hospital Of Guizhou Medical University · collabThe General Hospital of Western Theater Command · collab
NaSingle-groupOpen-labelTreatment
Summary
Although the anti-CD19 CAR-T cell therapies have gained significant results in patients with relapsed and refractory B-cell hematologic malignancies. There are patients who resisted anti-CD19 CAR-T cells or with CD19 negative relapse. To make further improvement, combining CD19 and CD22 as dual-targets for CAR-T cells, which adapt the FasT CAR-T cells manufacture technology to shorten the manufacture time and maintain the stemness of CAR-T cells. We launch such a clinical trial using CD19 and CD22 targeted CAR-T cells for patients with relapsed and refractory B-cell NHL to evaluate the efficacy and safety of CD19 and CD22 targeted CAR-T cell therapy.
Timeline
- Start
- 2020-05-01
- Primary completion
- 2021-05-01
- Completion
- 2023-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD19 and CD22 targeted CAR-T cells | Cell therapy | 100000 cells/kg | — |
| Subject | CD19 and CD22 targeted CAR-T cells | Cell therapy | 300000 cells/kg | — |
| Subject | CD19 and CD22 targeted CAR-T cells | Cell therapy | 600000 cells/kg | — |
| Subject | CD19 and CD22 targeted CAR-T cells | Cell therapy | 1e+06 cells/kg | — |